News

Livongo’s diabetes solution impresses in latest study

July 21, 2017

Livongo for Diabetes Program led to a drop in both high and low blood glucose readings.

Livongo’s diabetes solution impresses in latest study

https://pharmaphorum.com/news/livongo-diabetes-study/

Vifor’s hyperkalaemia drug Veltassa approved in Europe

July 21, 2017

Vifor Pharma has gained final European marketing approval for its hyperkalaemia treatment Veltassa. The approval is a major

Vifor’s hyperkalaemia drug Veltassa approved in Europe

https://pharmaphorum.com/news/vifors-hyperkalaemia-drug-veltassa-approved-europe/

New 3-year data supports Kite ‘cure’ hopes for CAR-T

July 21, 2017

A handful of patients with aggressive leukaemia appeared to have been cured thanks to CAR-T therapy, with some

New 3-year data supports Kite ‘cure’ hopes for CAR-T

https://pharmaphorum.com/news/new-3-year-data-supports-kite-cure-hopes-car-t/

Daiichi Sankyo anticoagulant gains EU label boost

July 21, 2017

Label gives guidance in use when restoring normal heart rhythm

Daiichi Sankyo anticoagulant gains EU label boost

https://pharmaphorum.com/news/daiichi-sankyo-noac-get-eu-label-boost/

Teva’s Cinqaero to challenge Nucala after clearing NICE

July 20, 2017

Discount swings NICE decision, drug will compete with GSK rival

Teva’s Cinqaero to challenge Nucala after clearing NICE

https://pharmaphorum.com/news/nice-recommends-teva-asthma-drug/

Ablynx and Sanofi sign potential 2.4bn euro R&D deal

July 20, 2017

Collaboration will develop drugs for inflammatory diseases

Ablynx and Sanofi sign potential 2.4bn euro R&D deal

https://pharmaphorum.com/news/ablynx-sanofi-sign-potential-2-4-bn-euros-rd-deal/

AliveCor and Mayo Clinic collaborate on heart screening tech

July 20, 2017

New tool will help screen for Long QT syndrome to prevent sudden deaths.

AliveCor and Mayo Clinic collaborate on heart screening tech

https://pharmaphorum.com/news/alivecor-mayo-sudden-death-screening/

Gilead’s latest hep C combo approved in US

July 20, 2017

Vosevi is aimed at tough to treat patients.

Gilead’s latest hep C combo approved in US

https://pharmaphorum.com/news/gileads-latest-hep-c-combo-approved-us/

GSK says goodnight to Horlicks, denies Brexit link

July 19, 2017

GlaxoSmithKline is to sell off its famous bedtime malted milk drink Horlicks in the UK, and will also

GSK says goodnight to Horlicks, denies Brexit link

https://pharmaphorum.com/news/gsk-says-goodnight-horlicks-denies-brexit-link/

1 2 3 4 5 >»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

News

News

Vifor’s hyperkalaemia drug Veltassa approved in Europe

New 3-year data supports Kite ‘cure’ hopes for CAR-T

Daiichi Sankyo anticoagulant gains EU label boost

Teva’s Cinqaero to challenge Nucala after clearing NICE

Ablynx and Sanofi sign potential 2.4bn euro R&D deal

Gilead’s latest hep C combo approved in US

GSK says goodnight to Horlicks, denies Brexit link

Inhalation and Respiratory Drug Products Summit

THET Annual Conference 2017

Clinical Trial Supply East Coast 2017

Livongo’s diabetes solution impresses in latest study

Vifor’s hyperkalaemia drug Veltassa approved in Europe

New 3-year data supports Kite ‘cure’ hopes for CAR-T

Daiichi Sankyo anticoagulant gains EU label boost

Teva’s Cinqaero to challenge Nucala after clearing NICE

The most notable digital health trends of 2017 so far

Europe has untapped medical innovation – but needs high speed connections to make it work

Healthcare’s hype cycle: which technologies will stay the course?

Looking back, looking forward – Janssen’s 60 years on the psychiatry horizon

What HCPs say about Roche’s breast cancer drug

Search

Advanced Search

Trending

News

News